A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils

L. Bjermer, C. Lemiere, J. Maspero, M. Ciesielska, C. O'Brien, J. Zangrilli (Lund, Sweden; Montreal, Canada; Buenos Aires, Argentina; Frazer, United States Of America)

Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Session: Clinical trials of drugs and biomarkers for respiratory diseases
Session type: Poster Discussion
Number: 299
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Bjermer, C. Lemiere, J. Maspero, M. Ciesielska, C. O'Brien, J. Zangrilli (Lund, Sweden; Montreal, Canada; Buenos Aires, Argentina; Frazer, United States Of America). A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Eur Respir J 2014; 44: Suppl. 58, 299

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014


Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015


Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016

The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014



Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials
Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies
Year: 2016


Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016


Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013

Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014


QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Aerobic training decreases bronchial hyperresponsiveness, serum chemokines and symptoms in asthmatic patients: Randomized controlled trial
Source: Annual Congress 2013 –Rehabilitation, exercise and adjunct physiotherapy techniques in different respiratory conditions
Year: 2013


Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013

Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014